GlassScriptPhysician profile
Chris Edens Marcellus
NPI 1336871904
$6,243.39
in general payments reported to CMS, 2019-2025
19 companies · $2,352 in 2025
The $2,352 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $849 · 2024: $3,042 · 2025: $2,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,184 · Education: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,183.99 |
| Education | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,188.80 | 2023-2025 | |
| Gilead Sciences, INC. | $728.92 | 2024-2025 | Epclusa, Livdelzi |
| Phathom Pharmaceuticals, INC. | $524.28 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $480.00 | 2023-2024 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $359.82 | 2023-2025 | Entyvio |
| Lilly USA, LLC | $350.01 | 2023-2024 | Omvoh, Zepbound |
| Janssen Biotech, INC. | $307.18 | 2023-2025 | Stelara, Tremfya |
| Evoke Pharma, INC. | $161.27 | 2023-2025 | Gimoti |
| Pfizer INC. | $156.08 | 2024 | |
| Intercept Pharmaceuticals, INC. | $144.17 | 2023-2024 | Ocaliva |
| Janssen Scientific Affairs, LLC | $131.93 | 2024 | Stelara |
| Ipsen Biopharmaceuticals, INC | $126.87 | 2024 | Iqirvo |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $124.65 | 2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $122.23 | 2023 | Zeposia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $78.89 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $60.62 | 2024 | Dupixent |
| Merck Sharp & Dohme LLC | $54.54 | 2024 | Dificid, Zerbaxa |
| Fresenius Kabi USA, LLC | $18.13 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Marcellus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.